| Autor: |
J, de Arístegui Fernández, J M, Corretger Rauet, F, García Martín, T, Hernández-Sampelayo, F A, Moraga Llop, C, Rodrigo Gonzalo De Liria, J, Ruiz Contreras |
| Rok vydání: |
2002 |
| Předmět: |
|
| Zdroj: |
Anales espanoles de pediatria. 56(1) |
| ISSN: |
0302-4342 |
| Popis: |
Pneumococcal disease is a major cause of morbidity, hospitalization and mortality. Two age groups show a greater incidence and severity of the disease: children under the age of 5 years (mainly during the first 2 years of life) and adults aged more than 65 years. The heptavalent pneumococcal conjugate vaccine, which was commercialized in Spain in June 2001, is efficacious in children aged less than 2 years and, unlike the non-conjugate 23-valent vaccine, it induces immunological memory. In Spain the heptavalent vaccine covers 80 % of serotypes causing pneumococcal invasive disease and acute otitis media in children aged 2-59 months. The heptavalent vaccine has been shown to be immunogenic, efficacious and safe. It has proven efficacy in the prevention of invasive disease caused by the seven vaccine serotypes. In addition, it significantly decreases pneumonia and also prevent acute otitis media. The vaccine is preferably indicated in children aged less than 2 years; children aged 2-5 years may also benefit from the vaccine but those in risk groups should be prioritized. Greater knowledge of the epidemiology of pneumococcal disease and the efficiency of this vaccine in Spain will determine whether it should be included in the immunization schedule. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
